Analysts think ANL stock price could increase by 249%
Nov 23, 2024, 12:27 PM
-17.87%
What does ANL do
Adlai Nortye is a clinical-stage biopharmaceutical company developing cancer therapies, including three clinical candidates: AN2025, AN0025, and AN4005, along with three preclinical candidates. AN2025 is in Phase III trials for treating recurrent head and neck squamous cell carcinomas.
2 analysts think ANL stock price will increase by 249.05%. The current median analyst target is $9.18 compared to a current stock price of $2.63. The lowest analysts target is $9.09 and the highest analyst target is $9.45.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.